Washington University in St. Louis has disclosed new autophagy inducers reported to be useful for the treatment of alpha-1 antitrypsin deficiency, amyotrophic lateral sclerosis, Alzheimer’s, Huntington’s and Parkinson’s disease.
Domain Therapeutics SA has prepared and tested new azine-based compounds acting as proteinase-activated receptor 2 (F2RL1; PAR2) inhibitors reported to be useful for the treatment of allergy, autoimmune, metabolic diseases, cardiovascular, dermatological, inflammatory disorders, pain and cancer.
Work at Pharmaengine Inc. has led to the identification of new protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Muna Therapeutics ApS has patented new triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, osteoporosis, rheumatoid arthritis, systemic lupus erythematosus, type 2 diabetes and obesity, among others.
Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain tumor in adults, marked by high treatment resistance and poor prognosis. OLIG2, a CNS-specific transcription factor essential for neural development, is highly expressed in GBM and contributes to tumor progression and therapy resistance, making it a promising target for novel therapeutic strategies.
Individuals with the inherited disorder Fanconi anemia cannot properly repair damage to their DNA, increasing risk of cancers such as head and neck squamous cell carcinoma (HNSCC).
Arcus Biosciences Inc. has announced five new research programs for autoimmune and inflammatory diseases, and is targeting initiation of the first clinical studies next year.
Beactica Therapeutics AB has held a first scientific advisory meeting with the Swedish Medical Products Agency (MPA) for BEA-17, the company’s first-in-class small-molecule targeted degrader of lysine demethylase 1 (LSD1) and its co-factor CoREST.
Chinese researchers have published preclinical data regarding the potential of never in mitosis A (NIMA)-related kinase 2 (NEK2) as a therapeutic target in multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system (CNS) in which B cells play a key role.
RSS
